---
document_datetime: 2024-09-04 12:33:53
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dovprela-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: dovprela-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.030727
conversion_datetime: 2025-12-31 01:41:35.20982
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Dovprela

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                   |
|----------------------|---------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0021              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation          | 03/09/2024                          |                                             | SmPC                             |                                                                                                                                                                           |
| II/0019/G            | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to | 16/05/2024                          | 28/06/2024                                  | SmPC and PL                      | For consistency and clarity, the wording of the indication section in the SmPC was updated to avoid conflicting information with respect to updated definitions for drug- |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | new quality, preclinical, clinical or pharmacovigilance data C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                      |            |            |                       | resistant TB from World Health Organization (WHO). Section 5.1 was also updated to specify the resistance profile of the patient populations studied in the ZeNix and NixTB clinical trials.   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0020             | updatindg addresses/names of manufacturers; updating raw material specifications, in-process tests and limits for the intermediate and finally extending the retest period of the active substance. B.I.z - Quality change - Active substance - Other variation | 11/04/2024 | n/a        |                       |                                                                                                                                                                                                |
| PSUSA/10863 /202308 | Periodic Safety Update EU Single assessment - pretomanid                                                                                                                                                                                                        | 07/03/2024 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                              |
| II/0013             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                               | 14/09/2023 | 15/11/2023 | SmPC, Annex II and PL | Please refer to Scientific Discussion 'Dovprela-H-C-005167- II-0013'                                                                                                                           |
| PSUSA/10863 /202302 | Periodic Safety Update EU Single assessment - pretomanid                                                                                                                                                                                                        | 28/09/2023 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                              |
| R/0015              | Renewal of the marketing authorisation.                                                                                                                                                                                                                         | 26/04/2023 | 23/06/2023 |                       |                                                                                                                                                                                                |
| IB/0017             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                       | 09/06/2023 | 04/10/2023 | SmPC                  |                                                                                                                                                                                                |
| PSUSA/10863 /202208 | Periodic Safety Update EU Single assessment - pretomanid                                                                                                                                                                                                        | 16/03/2023 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| IB/0014/G           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any   | 22/02/2023   | 23/06/2023   | SmPC, Annex II and PL   |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|-----------------------------------|
| PSUSA/10863 /202202 | Periodic Safety Update EU Single assessment - pretomanid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 29/09/2022   | n/a          |                         | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| R/0010              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                            | 22/04/2022   | 14/06/2022   | PL       | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Dovprela, subject to the Specific Obligations and Conditions as laid down in Annex II   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10863 /202108 | Periodic Safety Update EU Single assessment - pretomanid                                                                                                                                                                                                                                                                           | 10/03/2022   | n/a          |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0008             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                     | 13/01/2022   | 14/06/2022   | Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| PSUSA/10863 /202102 | Periodic Safety Update EU Single assessment - pretomanid                                                                                                                                                                                                                                                                           | 30/09/2021   | n/a          |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0004/G           | This was an application for a group of variations. Grouped application including three type II variations under category C.I.4. Update of sections 4.5 and 5.3 of the SmPC based on data from three non-clinical studies: - Assessment of pretomanid as an inhibitor of human OCT2-, OATP1B3-, BCRP-, and P-gp mediated transport; | 22/07/2021   | 14/06/2022   | SmPC     | SmPC new text '4.5 Interaction with other medicinal products and other forms of interaction Effects of pretomanid on other medicinal products […] Effect on CYP2C8, 2C9 and 2C19 substrates In vitro studies show that pretomanid is an inducer of CYP2C8 while the studies are inconclusive regarding the                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| - In vitro evaluation of induction/inhibition 2C8, 2C9, and 2C19 in human hepatocytes; - A 24-Month Oral (Gavage) Carcinogenicity Rats. C.I.4 - Change(s) in the SPC, Labelling new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling new quality, preclinical, clinical or pharmacovigilance data   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                     |            |            |                 | 5.3 Preclinical safety data […] In addition, in a 2-year carcinogenicity study in rats, pretomanid resulted in an increased incidence of cataracts at 10 mg/kg/day, resulting in an exposure in the same range as at the MRHD. The clinical relevance of this finding is unknown. […] In a 2-year study in rats, an increased incidence of Leydig cell adenomas was observed at a dose of 10 mg/kg/day. The observation is likely of limited relevance to humans.' For more information, please refer to the Summary of   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0005      | Renewal of the marketing authorisation.                                                                                                                                                                             | 22/04/2021 | 17/06/2021 |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IAIN/0006/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.7 - Administrative change - Deletion of manufacturing sites | 17/03/2021 | 17/06/2021 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0003     | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                             | 08/02/2021 | 17/06/2021 | SmPC            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| T/0002      | Transfer of Marketing Authorisation                                                                                                                                                                                 | 20/11/2020 | 14/01/2021 | SmPC,           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| A.2.a - Administrative change - Change in the medicinal product for CAPs   | 13/11/2020   | 11/01/2021   | Labelling and PL SmPC, Labelling and   | IAIN/0001 (invented) name of the   |
|----------------------------------------------------------------------------|--------------|--------------|----------------------------------------|------------------------------------|